Jason Aryeh - 08 Dec 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Reporting relationship: Director
Issuer ticker: LGND
Reported as of: 08 Dec 2025
Net transaction value: +$141,383
SEC form: 4
Accepted by SEC: 08 Dec 2025, 19:38:24 UTC
Prior SEC filing: 24 Sep 2025
Next SEC filing: 19 May 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Jason Aryeh

Key filing fact

Jason Aryeh filed Form 4 for LIGAND PHARMACEUTICALS INC (LGND) on 08 Dec 2025.

Key facts

This page summarizes Jason Aryeh's Form 4 filing for LIGAND PHARMACEUTICALS INC (LGND).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Dec 2025, 19:38.

Change

Previous filing in this sequence was filed on 24 Sep 2025.
Current net transaction value: +$141,383.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001376960 Primary reporting owner

Aryeh Jason

Relationship: Director
Address: 555 HERITAGE DRIVE, SUITE 200, JUPITER
Signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Jason Aryeh
Signature date: 08 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LGND transaction

Common Stock

Options Exercise

Transaction value: $141,383
Shares: +2,034
Change %: +2.9%
Price: $69.51
Shares after: 71,323
Date: 08 Dec 2025
Ownership: Direct

LGND holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 51,594
Date: 08 Dec 2025
Ownership: Indirect
Footnotes: F1

LGND holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,025
Date: 08 Dec 2025
Ownership: by Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LGND transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -2,034
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,034
Exercise price: $69.51
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.

Footnote F2

This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2016, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.